Last updated Jun 6, 2026
AstraZeneca
Evidence Sources
9
Competitive Findings
0
Portfolio Developments
2
Regulatory Precedents
4
Clinical Programs
2
Confidence Coverage
75%
Audit
- Competitor findings: 0
- Portfolio developments: 2
- Self-competition findings removed: 2
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Pulmonary Arterial Hypertension
- Prostacyclin Analog
- Respiratory
- COPD
Highest priority development: Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 75%
Active Signals
2
Investigate Priority
0
Opportunity Score
39
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 6, 2026Score 22FDA Accepts Supplement Application for Tyvaso (Treprostinil)
Pulmonary Arterial Hypertension · Prostacyclin Analog
- MonitorJun 1, 2026Score 17Study on NMES for Functional Recovery in COPD and Pneumonia Patients
Respiratory · COPD
Related Assets
Portfolio asset pages with evidence-based assessments.
- Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH MarketModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera - Tozorakimab's Phase III Success Positions it as Leader in COPD TreatmentModerate Confidence · 78%
Portfolio asset at Phase III stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)AstraZenecaClinicalTrials.govPortfolio
- AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class TreatmentLow Confidence · 0%
FDA approval
Sources (3)Humanexa SignalsFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- [SHINSA]List of therapeutic products for which eligible patients can be identified by Drug-Agnostic CDx,postedModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)PMDAPMDARegunera - FDA AP — BAXFENDY (ORIG)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — TYVASO (SUPPL)Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - [IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications openLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)PMDAPMDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH MarketModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov - Tozorakimab's Phase III Success Positions it as Leader in COPD TreatmentModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to AstraZeneca right now?
- Which regulatory precedents should AstraZeneca monitor in Pulmonary Arterial Hypertension and Prostacyclin Analog?
- How does Regulatory Developments Enhance Competitive Landscape for Tyvaso in PAH Market compare to the nearest competitive programs?
- What signals require immediate investigation for AstraZeneca?
- Summarize the strategic implications of recent developments for AstraZeneca.
- Where is the greatest uncertainty in AstraZeneca's competitive positioning?